MPX Bioceutical Corporation (CNSX:MPX) entered into a binding share purchase agreement to acquire Spartan Wellness Corporation from Ninth Square Capital Corporation and Veteran Grown Corporation for CAD 2.9 million on September 17, 2018. Under the terms of the agreement, MPX will acquire all of the Spartan shares for the following consideration which is partly based upon the achievement of certain milestones: i) issuance of 4,687,500 common shares in the capital of MPX and ii) issuance of 1,304,348 common share purchase warrants each exercisable into one MPX share at an exercise price of CAD 1.15 for a period of three years from the closing date. The first tranche of the aforementioned securities will be issued on closing with the remainder being issued based upon Spartan reaching certain milestones, including directing a percentage of its sales through Canveda Inc., a wholly owned subsidiary of MPX. As part of the transaction, MPX along with the sellers will create the Veteran Growth Fund using some MPX shares and warrants. At closing, MPX will issue 781,250 MPX shares and 108,696 warrants to sellers and 130,209 shares and 108,696 warrants for the fund. Further, upon achieving first sales milestone, MPX will issue 585,938 shares and 86,957 warrants to sellers and 130,208 shares and 108,696 warrants for the fund. Upon achieving second sales milestone, MPX will issue 585,937 shares and 86,957 warrants to sellers and 130,208 shares and 108,696 warrants for the fund. Upon achieving third sales milestone, MPX will issue 585,938 shares and 86,956 warrants to sellers and 130,208 shares and 108,696 warrants for the fund. Upon achieving fourth sales milestone, MPX will issue 585,937 shares and 65,217 warrants to sellers and 1,041,667 shares and 434,783 warrants for the fund. Following completion of the transaction, Spartan will be rebranded as “Spartan Wellness by MPX”. The transaction is expected to close on or about October 1, 2018. The acquisition is expected to immediately contribute to revenue growth at MPX.